stockportfolio.pro
Stocks / FDMT vs NRC
FDMT vs NRC
4D Molecular Therapeutics, Inc. and NRC Health side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| 4D Molecular Therapeutics, Inc. (FDMT) | NRC Health (NRC) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $85.21M | $137.39M |
| Net income (latest FY) | $-140.11M | $11.60M |
| Revenue growth (5y CAGR) | 44.3% | 0.6% |
| Net margin | -164.4% | 8.4% |
| Return on equity | -27.7% | 82.9% |
| P/E ratio | — | 49.5 |
| Dividend yield | — | 2.8% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open FDMT — free Open NRC — freeFrequently asked questions
Which is bigger, FDMT or NRC?
4D Molecular Therapeutics, Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, FDMT or NRC?
Over the last five fiscal years, 4D Molecular Therapeutics, Inc. grew revenue faster — 44.3%/yr versus 0.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.